Every provider promises a personalized treatment plan. We investigated what 'personalized' actually means — and what it doesn't.
GLP-1 'as low as' pricing almost always refers to your first month at the lowest dose. Here's what your actual maintenance-dose cost will be.
We read the cancellation terms of every major GLP-1 program. Some let you walk away anytime. Others make Planet Fitness look flexible.
We tested response times, escalation paths, and whether you can actually reach a human when something goes wrong.
Supply chain reports from the front lines. Which providers are shipping on time and which are stalling — and what that means for your treatment.
Both formats work. Neither is universally better. Here's what the evidence actually says — without the spin.
Our quarterly assessment of the GLP-1 telehealth market. Which providers raised their standards — and which ones slipped.
The way your provider bills you affects more than your bank account. It shapes your flexibility, your risk, and your options if things change.
Dozens of GLP-1 telehealth companies have already closed or pivoted. If yours is next, here's what happens to your treatment.
Lab work is the clearest signal of whether your provider is practicing medicine or just shipping medication. Here's what the best programs require.
Auto-refill schedules don't always match your actual usage. Here's how to avoid paying for medication you haven't used yet.
Any provider that guarantees you'll lose a specific number of pounds is violating medical ethics. Here's what legitimate programs say instead.
We tried to independently verify the compounding pharmacy behind each major GLP-1 program. Some made it easy. Others made it impossible.
Same molecule, very different products. Here's the honest comparison the industry doesn't want you to see.
Life changes. Your treatment needs change. Does your provider let you adapt — or do they penalize you for it?
There's a massive gap between 'ongoing medical support' in the marketing and what actually happens after your first shipment arrives.
The FDA's regulatory actions on 503B outsourcing facilities are reshaping the compounded GLP-1 market. Some providers saw it coming. Others didn't.
When can you expect to see results on semaglutide, tirzepatide, or orforglipron? We compare timelines from clinical trial data.
Every provider promises results. We looked at what they actually deliver — and where the gaps are.
Most GLP-1 patients hit a plateau between months 6-12. Here's the science behind it and evidence-based strategies to push through.
15-20% of GLP-1 patients are non-responders. Here's why it happens and what your options are if you're not losing weight.
Nausea, fatigue, constipation — most GLP-1 side effects are temporary. But these symptoms require immediate medical attention.
GLP-1 medications slow gastric emptying, which can change how other drugs are absorbed. These interactions matter most.
We read the terms of service so you don't have to. What we found should change how you compare GLP-1 programs.
GLP-1 medications treat both type 2 diabetes and obesity, but the prescribing approach differs. Here's what matters for each indication.
Your compounded GLP-1 comes from either a 503A or 503B pharmacy. The distinction affects quality, regulation, and future availability.
Exercise plus GLP-1 preserves muscle, boosts metabolism, and may improve long-term outcomes. Here's what the evidence supports.
Rapid weight loss on GLP-1s can weaken bones. Women over 50 face the highest risk. Here's what to monitor and how to protect yourself.
Semaglutide (Wegovy/Ozempic) vs tirzepatide (Zepbound/Mounjaro): efficacy, side effects, cost, and availability compared for June 2026.
Telehealth is faster and cheaper. In-person gives you lab work and physical exams. Here's how to decide which is right for your situation.
Medicare Part D beneficiaries can access GLP-1 medications for $50/month starting July 1. Here's how the Bridge program works and who qualifies.
Most GLP-1 ads show starting-dose prices. Here's what you'll actually pay at maintenance dose across 12 telehealth providers.
LegitScript certification separates vetted telehealth providers from the rest. Here's what it verifies and which GLP-1 platforms have it.
Eli Lilly's TRIUMPH-1 data shows retatrutide delivers 28% weight loss — rivaling bariatric surgery. What this triple agonist means for the future.
Switching GLP-1 providers doesn't mean starting over. Here's how to transfer your prescription, maintain your dose, and avoid gaps.
With Foundayo, oral semaglutide, and injectable options all available, choosing a GLP-1 format matters. We compare efficacy, cost, and convenience.
Men respond differently to GLP-1 medications — faster initial loss, different side effect profiles, and unique muscle preservation needs.
Not all GLP-1 telehealth providers are equal. These five red flags signal you should look elsewhere before committing.
New NIH research reveals the molecular pathways behind GLP-1 weight loss — and why some patients respond better than others.
Many GLP-1 users report dramatically reduced alcohol tolerance and cravings. Here's what the research says and what to watch for.
GLP-1 medications suppress appetite, but skipping protein accelerates muscle loss. Here's how much you need and why it matters.
Your titration schedule affects your results and your side effects. Not all providers handle it the same way — and the differences matter.
What to expect in your first 30 days on semaglutide or tirzepatide — from side effects to appetite changes to your first weigh-in.
Eli Lilly's oral GLP-1 pill Foundayo starts at $149/mo. Compounded semaglutide starts at $99-159/mo. We compare the real costs at every stage.
The FDA proposes permanently excluding semaglutide, tirzepatide, and liraglutide from 503B bulk compounding. Comment period closes June 29, 2026.
GLP-1 treatment isn't a 3-month fix — it's ongoing therapy. Here's how to calculate the real annual cost and find sustainable options.
Two GLP-1 pills, different trade-offs. Oral semaglutide has higher efficacy but strict fasting rules. Foundayo is flexible but less potent.
Compounded GLP-1s cost 60-80% less but aren't FDA-approved. Brand-name versions have clinical trial backing. Here's how to choose.
Oxford's BMJ meta-analysis found weight regain of 0.9 lbs/month after stopping GLP-1s. Here's what the data says — and how to plan for it.
New real-world data from ASCO 2026 shows GLP-1 medications may reduce metastatic progression in lung, breast, colorectal, and liver cancers.
775+ adverse events from compounded GLP-1. Here's how to tell if your telehealth provider is legitimate — and when to walk away.
Eli Lilly's triple-hormone drug is the most effective weight loss medication ever tested. It's also 2+ years away. Here's why starting now is smarter.
CMS launches $50/mo GLP-1 access for Medicare July 2026. We read every line of the announcement so you don't have to.
May 2026 NIH study: oral GLP-1 pills suppress eating for pleasure via deep brain pathways. Different mechanism than injectables.
Two GLP-1 pills, very different rules. We compare orforglipron (Foundayo) and oral Wegovy on dosing, efficacy, convenience, and pricing.
Prices dropped, pills launched, Medicare joined. The competitive landscape for GLP-1 medications has never been more favorable for patients.
Most sites show starting prices. We show what you'll actually pay at maintenance dose. Complete GLP-1 pricing at every titration step.
The April 30, 2026 FDA proposal to remove GLP-1s from the 503B Bulks List. We break down who benefits, who loses, and what it means for your medication.
75-80% weight maintenance sounds good. But what about the 20-25% you lose? We analyze the ATTAIN-MAINTAIN data honestly.
Compounded GLP-1 costs 50-80% less than brand. But is it the same medication? We compare cost, safety, legality, and efficacy with actual numbers.